Firstly, the mammalian Hippo pathway has redundant upstream negative regulators of YAP/TAZ (i.e. Mst1/2 and Lats 1/2) such that multiple mutations would be required to inactivate the pathway in a tumor. This evidence concerns the gene MST1 and neoplasm.